Tumor Biology

, Volume 36, Issue 3, pp 1367–1374 | Cite as

Hedgehog pathway aberrations and gastric cancer; evaluation of prognostic impact and exploration of therapeutic potentials

Review

Abstract

Gastric cancer is an important cause for mortality and morbidity worldwide; it lies in the fourt rank as a cause of cancer-related death in males and in the fifth rank of cancer-related death in women. The prognosis of advanced/metastatic gastric cancer cases looks poor with the majority of available therapeutics. Thus, novel therapeutic strategies in this setting have been considered a priority for leading cooperative oncology groups. Hedgehog(Hh) pathway aberrations have sparked particular interest as prognostic markers with data from multiple studies showing consistent evidence of a poor prognostic value of Gli over expression in gastric cancer while on the other hand the prognostic significance of Hh protein over expression (particularly SHH) was not consistent among different studies. This review article revises the prognostic and potential therapeutic opportunities in the targeting of hedgehog pathway in gastric cancer.

Keywords

Gastric cancer Hedghog Vismodegib 

Notes

Conflicts of interest

None

References

  1. 1.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMedGoogle Scholar
  2. 2.
    Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.CrossRefPubMedGoogle Scholar
  3. 3.
    Fitzgerald R, Hardwick R, Huntsman D. Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. J Med Genet. 2010;47:436–44.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Abdel-Rahman O. Insulin-like growth factor pathway aberrations and gastric cancer; evaluation of prognostic significance and assessment of therapeutic potentials. Med Oncol. 2015;32(1):431. doi: 10.1007/s12032-014-0431-8.CrossRefPubMedGoogle Scholar
  5. 5.
    Kordes S, Cats A, Meijer SL, van Laarhoven HW. Targeted therapy for advanced esophagogastric adenocarcinoma. Crit Rev Oncol Hematol. 2014;90:68–76.CrossRefPubMedGoogle Scholar
  6. 6.
    Abdel-Rahman O. Targeting the hepatocyte growth factor/mesenchymal epithelial transition pathway in gastric cancer: biological rationale and clinical applications. Expert Rev Anticancer Ther 2014;(0):1–11.Google Scholar
  7. 7.
    Abdel-Rahman O. Targeting vascular endothelial growth factor (VEGF) pathway in gastric cancer: preclinical and clinical aspects. Crit Rev Oncol Hematol. 2015;93(1):18–27.CrossRefPubMedGoogle Scholar
  8. 8.
    Ingham PW, McMahon AP. Hedgehog signaling in animal development: paradigms and principles. Genes Dev. 2001;15:3059–87.CrossRefPubMedGoogle Scholar
  9. 9.
    Riddle RD, Johnson RL, Laufer E, Tabin C. Sonic hedgehog mediates the polarizing activity of the ZPA. Cell. 1993;75:1401–16.CrossRefPubMedGoogle Scholar
  10. 10.
    Echelard Y et al. Sonic hedgehog, a member of a family of putative signaling molecules, is implicated in the regulation of CNS polarity. Cell. 1993;75:1417–30.CrossRefPubMedGoogle Scholar
  11. 11.
    Stecca B, Ruiz I, Altaba A. Context-dependent regulation of the GLI code in cancer by HEDGEHOG and non-HEDGEHOG signals. J Mol Cell Biol. 2010;2:84–95.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Wang B, Fallon JF, Beachy PA. Hedgehog-regulated processing of Gli3 produces an anterior/posterior repressor gradient in the developing vertebrate limb. Cell. 2000;100:423–34.CrossRefPubMedGoogle Scholar
  13. 13.
    Kim JH, Choi YJ, Lee SH, Shin HS, Lee IO, Kim YJ, et al. Effect of Helicobacter pylori infection on the sonic hedgehog signaling pathway in gastric cancer cells. Oncol Rep. 2010;23(6):1523–8.PubMedGoogle Scholar
  14. 14.
    Yang L, Huang S, Bian Y, Ma X, Zhang H, Xie J. Identification of signature genes for detecting hedgehog signaling activation in gastric cancer. Mol Med Rep. 2010;3(3):473.PubMedPubMedCentralGoogle Scholar
  15. 15.
    Yan R, Peng X, Yuan X, Huang D, Chen J, Lu Q, et al. Suppression of growth and migration by blocking the hedgehog signaling pathway in gastric cancer cells. Cell Oncol. 2013;36(5):421–35.CrossRefGoogle Scholar
  16. 16.
    Lee SJ, Do IG, Lee J, Kim KM, Jang J, Sohn I, et al. Gastric cancer (GC) patients with hedgehog pathway activation: PTCH1 and GLI2 as independent prognostic factors. Target Oncol. 2013;8(4):271–80.CrossRefPubMedGoogle Scholar
  17. 17.
    Niu Y, Li F, Tang B, Shi Y, Hao Y, Yu P, et al. Clinicopathological correlation and prognostic significance of sonic hedgehog protein overexpression in human gastric cancer. Int J Clin Exp Pathol. 2014;7(8):5144–53. eCollection 2014.PubMedPubMedCentralGoogle Scholar
  18. 18.
    Kim JY, Ko GH, Lee YJ, Ha WS, Choi SK, Jung EJ, et al. Prognostic value of sonic hedgehog protein expression in gastric cancer. Jpn J Clin Oncol. 2012;42(11):1054–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Yoo YA, Kang MH, Lee HJ, Kim BH, Park JK, Kim HK, et al. Sonic hedgehog pathway promotes metastasis and lymphangiogenesis via activation of Akt, EMT, and MMP-9 pathway in gastric cancer. Cancer Res. 2011;71(22):7061–70.CrossRefPubMedGoogle Scholar
  20. 20.
    Zhang C, Li C, He F, Cai Y, Yang H. Identification of CD44+ CD24+ gastric cancer stem cells. J Cancer Res Clin Oncol. 2011;137(11):1679–86.CrossRefPubMedGoogle Scholar
  21. 21.
    Song Z, Yue W, Wei B, Wang N, Li T, Guan L, et al. Sonic hedgehog pathway is essential for maintenance of cancer stem-like cells in human gastric cancer. PLoS One. 2011;6(3):e17687.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Wang XD, Inzunza H, Chang H, Qi Z, Hu B, Malone D, et al. Mutations in the hedgehog pathway genes SMO and PTCH1 in human gastric tumors. PLoS One. 2013;8(1):e54415.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Fukaya M, Isohata N, Ohta H, Aoyagi K, Ochiya T, Saeki N, et al. Hedgehog signal activation in gastric pit cell and in diffuse-type gastric cancer. Gastroenterology. 2006;131(1):14–29.CrossRefPubMedGoogle Scholar
  24. 24.
    di Magliano Pasca M, Hebrok M. Hedgehog signalling in cancer formation and maintenance. Nat Rev Cancer. 2003;3:903–11.CrossRefGoogle Scholar
  25. 25.
    Stanton BZ, Peng LF, Maloof N, Nakai K, Wang X, Duffner JL, et al. A small molecule that binds Hedgehog and blocks its signaling in human cells. Nat Chem Biol. 2009;5(3):154–6. doi: 10.1038/nchembio.142.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Von Hoff D, Rudin C, LoRusso P, Borad M, Korn R, Heath E, et al. Efficacy data of GDC-0449, a systemic Hedgehog pathway antagonist, in a first-in-human, first-in-class Phase I study with locally advanced, multifocal or metastatic basal cell carcinoma patients; AACR Meeting Abstracts; 2008; 2008. LB-138.Google Scholar
  27. 27.
    Wu X, Ding S, Schultz PG. Compounds and composition as hedgehog pathway modulators. WO2006050351. 2006.Google Scholar
  28. 28.
    Song Y, Tian Y, Zuo Y, Tu JC, Feng YF, Qu CJ. Altered expression of PTCH and HHIP in gastric cancer through their gene promoter methylation: novel targets for gastric cancer. Mol Med Rep. 2013;7(4):1159–68.PubMedGoogle Scholar
  29. 29.
    Yan R, Peng X, Yuan X, Huang D, Chen J, Lu Q, et al. Suppression of growth and migration by blocking the hedgehog signaling pathway in gastric cancer cells. Cell Oncol. 2013;36(5):421–35.CrossRefGoogle Scholar
  30. 30.
    Wan J, Zhou J, Zhao H, Wang M, Wei Z, Gao H, et al. Sonic hedgehog pathway contributes to gastric cancer cell growth and proliferation. BioRes Open Access. 2014;3(2):53–9.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366(23):2171–9.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Tang JY, Mackay-Wiggan JM, Aszterbaum M, Yauch RL, Lindgren J, Chang K, et al. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med. 2012;366(23):2180–8.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Kaye SB, Fehrenbacher L, Holloway R, Amit A, Karlan B, Slomovitz B, et al. A phase II, randomized, placebo-controlled study of vismodegib as maintenance therapy in patients with ovarian cancer in second or third complete remission. Clin Cancer Res. 2012;18(23):6509–18.CrossRefPubMedGoogle Scholar
  34. 34.
    Berlin J, Bendell JC, Hart LL, Firdaus I, Gore I, Hermann RC, et al. A randomized phase II trial of vismodegib versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer. Clin Cancer Res. 2013;19(1):258–67.CrossRefPubMedGoogle Scholar
  35. 35.
    Cohen DJ, Christos PJ, Sparano JA, Kindler HL, Catenacci DVT, Bekaii-Saab TB, et al. A randomized phase II study of vismodegib (V), a hedgehog (HH) pathway inhibitor, combined with FOLFOX in patients (pts) with advanced gastric and gastroesophageal junction (GEJ) carcinoma: a New York Cancer Consortium led study. J Clin Oncol 2013;31:(4).Google Scholar
  36. 36.
    Kameda C, Nakamura M, Tanaka H, Yamasaki A, Kubo M, Tanaka M, et al. Oestrogen receptor-α contributes to the regulation of the hedgehog signalling pathway in ERα-positive gastric cancer. Br J Cancer. 2010;102(4):738–47.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Yoon C, Park DJ, Schmidt B, Thomas NJ, Lee HJ, Kim TS, et al. CD44 expression denotes a subpopulation of gastric cancer cells in which Hedgehog signaling promotes chemotherapy resistance. Clin Cancer Res. 2014;20(15):3974–88.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  1. 1.Clinical Oncology Department, Faculty of MedicineAin shams UniversityCairoEgypt

Personalised recommendations